Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06058377
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2023-09-27
Brief Title:
Adding an Immunotherapy Drug MEDI4736 Durvalumab to the Usual Chemotherapy Treatment Paclitaxel Cyclophosphamide and Doxorubicin for Stage II-III Breast Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Hormone Receptor-Positive Breast Carcinoma |
| Anatomic Stage II Breast Cancer AJCC v8 |
| Anatomic Stage III Breast Cancer AJCC v8 |
| HER2-Negative Breast Carcinoma |
| Localized Breast Carcinoma |
Keywords: